Form 6-K ARGENX SE For: Jun 30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/7/2026


July 31, 2025 8:16 AM UTC
0001697862FALSE2025-06-30Q2--12-310.33330.027830.25iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesiso4217:EURxbrli:pureargx:equityInstrumentargx:Yutr:Yargx:segmentargx:customer00016978622025-01-012025-06-3000016978622025-06-3000016978622024-12-3100016978622024-01-012024-06-3000016978622023-12-3100016978622024-06-300001697862ifrs-full:IssuedCapitalMember2023-12-310001697862ifrs-full:SharePremiumMember2023-12-310001697862ifrs-full:RetainedEarningsMember2023-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2023-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2023-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2023-12-310001697862ifrs-full:RetainedEarningsMember2024-01-012024-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-01-012024-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-01-012024-06-300001697862ifrs-full:IssuedCapitalMember2024-01-012024-06-300001697862ifrs-full:SharePremiumMember2024-01-012024-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-01-012024-06-300001697862ifrs-full:IssuedCapitalMember2024-06-300001697862ifrs-full:SharePremiumMember2024-06-300001697862ifrs-full:RetainedEarningsMember2024-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-06-300001697862ifrs-full:IssuedCapitalMember2024-12-310001697862ifrs-full:SharePremiumMember2024-12-310001697862ifrs-full:RetainedEarningsMember2024-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-12-310001697862ifrs-full:RetainedEarningsMember2025-01-012025-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2025-01-012025-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2025-01-012025-06-300001697862ifrs-full:IssuedCapitalMember2025-01-012025-06-300001697862ifrs-full:SharePremiumMember2025-01-012025-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2025-01-012025-06-300001697862ifrs-full:IssuedCapitalMember2025-06-300001697862ifrs-full:SharePremiumMember2025-06-300001697862ifrs-full:RetainedEarningsMember2025-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2025-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2025-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2025-06-300001697862ifrs-full:TradeReceivablesMemberifrs-full:AccumulatedImpairmentMember2025-06-300001697862ifrs-full:TradeReceivablesMemberifrs-full:AccumulatedImpairmentMember2024-12-310001697862argx:TermAccountsMember2025-06-300001697862argx:TermAccountsMember2024-06-300001697862currency:EUR2025-06-300001697862argx:ShareBasedCompensationAwardTrancheOneMember2025-01-012025-06-300001697862argx:ShareBasedCompensationAwardTrancheTwoMember2025-01-012025-06-300001697862argx:StockOptionPlanMemberargx:NonExecutiveDirectorMember2025-01-012025-06-300001697862argx:IfrsRestrictedStockUnitsRsusMember2025-01-012025-06-3000016978622025-03-012025-03-3100016978622025-06-012025-06-300001697862ifrs-full:BottomOfRangeMember2025-03-012025-03-310001697862ifrs-full:TopOfRangeMember2025-03-012025-03-310001697862ifrs-full:BottomOfRangeMember2025-06-012025-06-300001697862ifrs-full:TopOfRangeMember2025-06-012025-06-3000016978622025-03-310001697862argx:BelgianTaxedBeneficiariesMember2025-01-012025-06-300001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:BottomOfRangeMember2025-01-012025-06-300001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:TopOfRangeMember2025-01-012025-06-300001697862ifrs-full:BottomOfRangeMember2025-01-012025-06-300001697862ifrs-full:TopOfRangeMember2024-06-012024-06-300001697862argx:IfrsRestrictedStockUnitsRsusMember2024-01-012024-12-310001697862argx:IfrsRestrictedStockUnitsRsusMemberargx:NonExecutiveDirectorMember2024-01-012024-12-310001697862argx:IfrsRestrictedStockUnitsRsusMemberargx:NonExecutiveDirectorMember2025-01-012025-06-300001697862argx:IfrsRestrictedStockUnitsRsusMember2024-01-012024-06-300001697862argx:PerformanceStockUnitsPSUsMember2025-01-012025-06-300001697862argx:PerformanceStockUnitsPSUsMember2025-06-302025-06-300001697862argx:RebatesAndChargeBacksMember2024-12-310001697862argx:DistributionFeesAndProductReturnsMember2024-12-310001697862argx:RebatesAndChargeBacksMember2025-01-012025-06-300001697862argx:DistributionFeesAndProductReturnsMember2025-01-012025-06-300001697862argx:RebatesAndChargeBacksMember2025-06-300001697862argx:DistributionFeesAndProductReturnsMember2025-06-300001697862country:US2025-01-012025-06-300001697862country:US2024-01-012024-06-300001697862country:JP2025-01-012025-06-300001697862country:JP2024-01-012024-06-300001697862country:CN2025-01-012025-06-300001697862country:CN2024-01-012024-06-300001697862country:NL2025-01-012025-06-300001697862country:NL2024-01-012024-06-300001697862argx:RestOfTheWorldMember2025-01-012025-06-300001697862argx:RestOfTheWorldMember2024-01-012024-06-300001697862argx:OncoVerityInc.JointVentureMember2025-06-300001697862argx:OncoVerityInc.JointVentureMember2024-12-310001697862argx:ExecutiveDirectorsMember2025-01-012025-06-300001697862argx:PerformanceStockUnitsPSUsMemberargx:ExecutiveDirectorsMember2025-01-012025-06-300001697862argx:HalozymeTherapeuticsIncMember2019-02-280001697862argx:LonzaMemberargx:EfgartigimodMember2025-06-300001697862argx:FujifilmMemberargx:EfgartigimodMember2025-06-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2025

Commission File Number: 001-38097

ARGENX SE
(Translation of registrant’s name into English)
Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands.
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐






argenx SE
On July 31, 2025, argenx SE (the “Company) issued a press release, unaudited first half-year financial results for 2025, which are further described in an Unaudited Interim Report for the Six Months Ended June 30, 2025, and an investor presentation copies of which are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are incorporated by reference herein.

The information contained in this Current Report on Form 6-K, including Exhibit 99.1 and Exhibit 99.2, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-225375, 333-258253, and 333-274721), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.




EXHIBITS
ExhibitDescription
99.1
99.2
99.3
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL)






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ARGENX SE
Date: July 31, 2025
By:
 /s/ Hemamalini (Malini) Moorthy
Hemamalini (Malini) Moorthy
General Counsel

ATTACHMENTS / EXHIBITS

EX-99.1

EX-99.2

EX-99.3

XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: R49.htm

IDEA: R50.htm

IDEA: R51.htm

IDEA: R52.htm

IDEA: R53.htm

IDEA: R54.htm

IDEA: R55.htm

IDEA: R56.htm

IDEA: R57.htm

IDEA: R58.htm

IDEA: R59.htm

IDEA: R60.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: argx-20250630_htm.xml


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings